Avalanche Biotechnologies Inc  

(Public, NASDAQ:AAVL)   Watch this stock  
Find more results for Paul Wachter
+0.44 (3.08%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.21 - 15.28
52 week 14.01 - 62.48
Open 14.37
Vol / Avg. 301,027.00/803,218.00
Mkt cap 375.79M
P/E     -
Div/yield     -
EPS -1.73
Shares 25.53M
Beta     -
Inst. own 68%
Jun 15, 2015
Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration - Webcast
May 13, 2015
Q1 2015 Avalanche Biotechnologies Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -4684.24% -4441.26%
Operating margin -4709.85% -4301.75%
EBITD margin - -4237.76%
Return on average assets -16.78% -31.17%
Return on average equity -17.77% -40.54%
Employees 64 -
CDP Score - -


1035 O?Brien Drive, Suite A
United States - Map
+1-650-2726269 (Phone)
+1-650-3621908 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Avalanche Biotechnologies, Inc. (Avalanche) is a clinical-stage biotechnology company. The Company is focused on discovering and developing gene therapies for patients with sight-threatening ophthalmic diseases. The Company uses its gene therapy platform, the Ocular BioFactory, to create a pipeline of product candidates. The Company's product candidates include AVA-101, AVA-201 and AVA-311. The Company is developing its lead product candidate, AVA-101, which is indicated for the treatment for wet age-related macular degeneration (AMD). AVA-201 is the Company's next generation anti-vascular endothelial growth factor (anti-VEGF) gene therapy product candidate, which it is developing for the prevention of wet AMD. The Company is conducting preclinical studies on AVA-311 for the treatment of Juvenile X-linked Retinoschisis (XLRS).

Officers and directors

Mark S. Blumenkranz M.D. Chairman of the Board, Co-Founder
Age: 64
Bio & Compensation  - Reuters
Hans P. Hull Interim President and Chief Executive Officer
Age: 40
Bio & Compensation  - Reuters
Steven D. Schwartz M.D. Co-Founder, Director
Age: 53
Bio & Compensation  - Reuters
Linda C. Bain CPA Chief Financial Officer, Treasurer
Age: 44
Bio & Compensation  - Reuters
Roman G. Rubio M.D. Senior Vice President and Head - Translational Medicine
Age: 44
Bio & Compensation  - Reuters
Mehdi Gasmi Ph.D. Interim Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Samuel B. Barone M.D. Chief Medical Officer
Age: 42
Bio & Compensation  - Reuters
John P. McLaughlin Director
Age: 63
Bio & Compensation  - Reuters
Paul D. Wachter Director
Age: 58
Bio & Compensation  - Reuters